INOVIQ Validates EXO-OC Ovarian Cancer Test, Advances CAR-Exosome Therapy

• EXO-OC test achieves 77% sensitivity and >99.6% specificity for ovarian cancer detection
• 100% sensitivity for early-stage ovarian cancer (Stage I/II) in clinical validation
• CAR-exosomes demonstrate 88% in vitro killing of triple-negative breast cancer and non-small cell lung cancer cells
• Strategic US FDA regulatory pathway planned with initial LDT launch and subsequent IVD approval